HER2 testing to manage patients with breast cancer or other solid tumors.

Evidence report/technology assessment

Volumn , Issue 172, 2008, Pages 1-362

  Seidenfeld, Jerome ^a   Samsom, David J ^a   Rothenberg, Barbara M ^a   Bonnell, Claudia J ^a   Ziegler, Kathleen M ^a   Aronson, Naomi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

BLOOD; BREAST TUMOR; FEMALE; HEAD AND NECK TUMOR; HUMAN; LUNG TUMOR; OVARY TUMOR; PREDICTION AND FORECASTING; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2;

EID: 65649137411     PISSN: 15304396     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (235)